Lexipafant(BB-882), A Potent PAF Antagonist in Acute Pancreatitis

  • Lloyd D. Curtis
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 416)

Abstract

Acute pancreatitis remains a poorly understood and hence unsatisfactorily treated condition1. In general this is a mild self-limiting disease, which resolves within days and can be managed with non-specific supportive measures and analgesia. In about 25% of cases, however, the disease becomes severe, (defined as pancreatitis associated with organ failure or a local complication such as abscess, pseudocyst or necrosis2). It is this severe group that accounts for much of the morbidity and mortality of the disease. The overall mortality is reported at about 8–10%3, and this occurs almost exclusively in those with severe disease. Published series have shown that organ failure and particularly respiratory failure are the most common complications.

Keywords

Acute Pancreatitis Organ Failure Severe Acute Pancreatitis Experimental Pancreatitis Organ System Failure 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Fernandez-del Castillo C, Rattner DW, Warshaw AL. Acute Pancreatitis. Lancet 1993; 342: 475–479.CrossRefGoogle Scholar
  2. 2.
    Bradley EL. A Clinically based classification system for acute pancreatitis. summary of the International Symposium on Acute Pancreatitis, Atlanta, Ga, September 11 through 13, 1992. Arch Surg 1993; 128: 586–590.Google Scholar
  3. 3.
    Larvin M. McMahon MJ. Apache-II score for assessment and monitoring of acute pancreatitis. Lancet 1989;:201–205.Google Scholar
  4. 4.
    Heath D, Alexander D, Wilson C, Larvin M, Imrie CW, McMahon. Which complications of acute pancreatitis are most lethal? A prospective multi-centre study of 719 attacks. Gut 1995; 36: 3, A478.Google Scholar
  5. 5.
    McFadden D.W. Organ failure and multiple organ system failure in pancreatitis. Pancreas 1991;6, Suppl. 1: S37 - S43.Google Scholar
  6. 6.
    Buchler M, Malfertheiner P, Uhl W, et al. Gabexate mesilate in human acute pancreatitis. Gastroenterology 1992; 104: 1165–1170.Google Scholar
  7. 7.
    Imrie CW, Benjamin IS, Ferguson JC, McKay AJ, Mackenzie I, O’Neill J, Blumgart LH. A single-centre double blind trial of Trasylol therapy in primary acute pancreatitis. Br J Surg 1978; 65: 337–341.PubMedCrossRefGoogle Scholar
  8. 8.
    Bone RC, Balk RA, Cerra FB et al. ACCP/SCCM consensus conference: definitions for Sepsis and Organ failure and Guidelines for the Use of Innovative Therapies in Sepsis. Chest 1992; 101: 1644–1655.PubMedCrossRefGoogle Scholar
  9. 9.
    Konturek SJ, Dembinski A, Konturek PJ, Warzecha Z, Jaworek J, Grustaw P, R Tomasxewska R, Stachura J. Role of platelet activating factor in pathogenesis of acute pancreatitis in rats. Gut 1992; 33: 1268–1274.PubMedCrossRefGoogle Scholar
  10. 10.
    Emanuelli G, Montrucchio G, Gaia E, Gughera L, Corvetti G, Gurbetta L. Experimental acute pancreatitis induced by platelet activating factor in rabbits. Am JPath 1989; 134: 315–326.Google Scholar
  11. 11.
    Zhou W, Mcollum MO, Levine BA, Olson MS. Role of platelet activating factor in pancreatitis-associated lung injury in the rat. Am J Path 1992; 140: 971–979.PubMedGoogle Scholar
  12. 12.
    Guillermo A, Lopez Farre A, Gomez Garre DN, Novo C, Romeo JM, Branquet P, Lopez-Novoa JM. Role of platelet activating factor in haemodynamic derangements in an acute rodent pancreatic model. Gastroenterology 1992; 102: 181–187.Google Scholar
  13. 13.
    Chank SW, Fedderson CO, Henson PM, Voelkel NF. Platelet activating factor mediates haemodynamic changes and lung injury in endotoxin-treated rats. J Clin Invest 1987;79:1498–1509. Google Scholar
  14. 14.
    Formela LJ, Wood LM, Whittaker M, Kingsnorth AN. Amelioration of experimental acute pancreatitis with a potent platelet-activating factor antagonist. Br J Surg 1994; 81: 1783–1785.PubMedCrossRefGoogle Scholar
  15. 15.
    Galloway SW, Kingsnorth AN. Lung injury in the microembolic model of acute pancreatitis and amelioration by a platelet-activating factor antagonist. Pancreas 1995. In press.Google Scholar
  16. 16.
    Kingsorth AN, Galloway SW, Formela LJ. Randomized, double-blind phase II trial of lexipafant, a platelet-activating factor antagonist in human pancreatitis. British J of Surg 1995. In Press.Google Scholar

Copyright information

© Springer Science+Business Media New York 1996

Authors and Affiliations

  • Lloyd D. Curtis
    • 1
  1. 1.British Biotech Pharmaceuticals LimitedOxfordUK

Personalised recommendations